Bone metastasis is a frequent occurrence in prostate cancer patients and often is lethal. Zoledronic acid (ZOL) is often used for bone metastasis with limited efficacy. More effective models and treatment methods are required to improve the outcome of prostate cancer patients. In the present study, the effects of tumor-targeting
INTRODUCTION
Prostate cancer is diagnosed in more than 500,000 men worldwide [1] . Bone metastases from prostate cancer can cause chronic pain, hypercalcemia, pathologic fractures, and nerve compression [2] . Zoledronic acid (ZOL), a bisphosphonate, has been used to prevent the development of metastatic bone lesions. Although bisphosphonates, irradiation, and surgical resection of tumors are used as treatments of bone metastases, the outcomes of the treatments are still unsatisfactory.
Salmonella typhimuium (S. typhimurium) A1-R, is a genetically-engineered strain of Salmonella that is able to specifically target cancer cells [3] . S. typhimurium A1-R was able to inhibit or eradicate primary and metastatic tumors as monotherapy in nude mouse models of prostate [3, 4] , breast [5] [6] [7] , lung [8, 9] , pancreatic [10] [11] [12] [13] [14] , ovarian [15, 16] , stomach [17] and cervical cancer [18] , as well as sarcoma [19] [20] [21] [22] [23] and glioma [24, 25] , all of which are highly aggressive tumor models. Tumors with a high degree of vascularity were more sensitive to S. typhimurium A1-R, and vascular destruction appears to play a role in S. typhimurium A1-R antitumor efficacy [25] . Tumor vessel destruction and tumor-growth inhibition were enhanced by primer dosing of S. typhimurium A1-R in immunocompetent transgenic mice expressing the nestin-driven green fluorescent protein (ND-GFP), which is selectively expressed in nascent blood vessels [26] .
In the present study, the efficacy of S. typhimurium A1-R and the combination of S. typhimurium A1-R and ZOL was assessed in nude mice models of solitary and multiple bone metastases of prostate cancer.
RESULTS AND DISCUSSION

Efficacy of S. typhimurium A1-R on human prostate cancer cells in vitro
To determine the efficacy of A1-R on prostate cancer cells, PC-3-RFP cells were incubated in 35 mm dishes for 24 h, and the cells were treated with S. typhimurium A1-R for 1 h. The cells were observed with a Fluoview FV1000 confocal microscope (Olympus Corp., Tokyo, Japan). Fluorescence imaging demonstrated that S. typhimurium A1-R expressing GFP selectively invaded and replicated intracellularly and killed PC-3-RFP cells ( Figure 1 ). Clonogenic assays demonstrated that S. typhimurium A1-R inhibited proliferation of PC-3-RFP cells in a dosedependent manner ( Figure 2 ).
Efficacy of S. typhimurium A1-R therapy on a mouse model of multiple bone metastasis
Nude mice were injected in the left ventricle with PC-3-GFP cells (5 × 10 5 ). One week after intracardiac injection, half of the mice were treated once a week for 3 weeks with an i.v. injection of S. typhimurium A1-R (5 × 10 7 CFU) ( Figure 3a ). Time-course fluorescence imaging of the study mice revealed GFP-expressing tumor growth in the control group and little tumor growth in the S. typhimurium A1-R group (Figure 3b ). S. typhimurium A1-R significantly improved the metastasis-free survival and overall survival of the mice (Figure 3c h. The cells were treated with S. typhimurium A1-R for 1 h. The PC-3-RFP cells were rinsed with PBS and the cells were observed with the FV1000 confocal microscope. Fluorescence images were obtained at 24 hours after infection and demonstrated that S. typhimurium A1-R expressing GFP invaded a. and replicated intracellularly b. in PC-3-RFP cells. After the invasion and replication of GFP-expressing S. typhimuium A1-R, the infected cells shrunk c. and fragmented d.. See Materials and Methods for details. www.impactjournals.com/oncotarget
Efficacy of S. typhimurium A1-R on a mouse model of solitary bone metastasis of prostate cancer
PC-3-RFP (5 × 10 5 ) cells were injected into the intramedullary cavity of the tibia in nude mice ( Figure 4a ). One week after the injection, the mice were divided into 4 groups: a control group, a ZOL group, an A1-R group, and a ZOL+ S. typhimurium A1-R group. ZOL-group mice were treated with subcutaneous injection of ZOL (120 mg/ kg) (Sigma-Aldrich. St. Louis, MO) 5 times a week for 4 weeks (Figure 4b ). S. typhimurium A1-R group mice were treated with weekly i.v. injections of S. typhimurium A1-R (5 × 10 7 CFU) for a total of 3 weeks. ZOL+ S. typhimurium A1-R-group mice were treated with both s.c. injection of ZOL and i.v. injection of S. typhimurium A1-R at the same dosages listed above. Fluorescence imaging was performed with an iBOX Scientia Imaging System (UVP, LLC, Upland, CA) every week. The fluorescence images demonstrated that the control group had rapid growth of metastatic bone cancer, whereas the ZOL group, S. typhimurium A1-R group, and the ZOL+S. typhimurium A1-R group mice had reduced metastatic growth ( Figure  4c ). The fluorescent tumor area of the control-group mice was 54.9 ± 6.1 mm 2 , ZOL group at 4 weeks mice was 29.1 ± 9.2 mm 2 , S. typhimurium A1-R-group mice was 23.8 ± 6.1 mm 2 , and ZOL+ S. typhimurium A1-R group mice was 18.4 ± 5.3 mm 2 (Figure 4d ). The S. typhimurium A1-R group and the ZOL+ S. typhimurium A1-R group had significant inhibition of tumor growth compared to the control group. Four weeks after the injection of cancer cells, the mice were sacrificed and tumor weight was measured. Tumor weights of the control group was 2.6 ± 0.6 g; ZOL group was 0.5 ± 0.2 g; S. typhimurium A1-R group was 1.1 ± 0.6; and ZOL+ S. typhimurium A1-R group mice at 4 weeks was 0.3 ± 0.1 g (Figure 4e ).
The tumor targeting of prostate cancer-bone metastasis strategy, developed in the present report, could also be used with previously-developed tumor targeting strategies [27] [28] [29] [30] [31] [32] [33] [34] .
The present study demonstrates that S. typhimuium A1-R could significantly inhibit or prevent prostate cancer metastasis in the bone. These results indicate a promising approach to a currently highly treatment-resistant disease. 
MATERIALS AND METHODS
Cell culture
PC-3 cells, which were originally established from metastatic bone lesions of human prostate cancer [35] , were labeled with GFP or RFP. PC-3-RFP and PC-3-GFP cells were generated as previously described [36] [37] [38] [39] . Cells were maintained in RPMI 1640 with 10% FBS + 1% penicillin streptomycin solution. Cells were subcultured for at least 3 passages before harvesting at their linear growth phase (approximately 70-80% confluent) for intracardiac or intramedullaly injection at 5 × 10 5 cells/ mouse.
Animal care
Athymic nude mice (nu/nu) (AntiCancer Inc, San Diego, CA) were used in this study. Mice were maintained in a barrier facility of high efficiency particulate air-filtered racks. The animals were fed an autoclaved laboratory rodent diet. Animal experiments were performed in accordance with the Guidelines for the Care and Use of Laboratory Animals under National Institutes of Health assurance number A3873-01.
Preparation of S. typhimurium A1-R
GFP-expressing S. typhimurium A1-R bacteria (AntiCancer Inc., San Diego, CA, USA) were grown overnight on LB medium (Fisher Sci., Hanover Park, IL, USA) and then diluted 1:10 in LB medium. Bacteria were harvested at late-log phase, washed with PBS, and then diluted in PBS [3, 5] .
S. typhimurium A1-R killing of prostate cancer cells in vitro
PC-3-RFP cells were plated in 35 mm dishes (5 × 10 2 cells/dish). S. typhimurium A1-R-GFP was added to the cancer cells (1 × 10 7 or 1 × 10 8 CFU/dish). After 1 h incubation at 37°C, the cells were rinsed and cultured in medium containing gentamycin sulfate (100 µg/ml) to kill external but not internal bacteria. Invasion and destruction of PC-3-RFP cells by S. typhimurium A1-R-GFP was visualized with a Fluoview FV1000 confocal microscope (Olympus Corp., Tokyo, Japan). Eight days after treatment with S. typhimurium A1-R, PC-3-RFP colonies were fixed in methanol and stained with 1% crystal violet as previously described [40] . ImageJ (National Institute of Mental Health, Bethesda, Maryland, USA) was used to quantify the area of the colonies of the cells.
Efficacy of S. typhimurium A1-R therapy on a mouse model of multiple bone metastases
PC-3-GFP cells (5 × 10 5 ) were injected intracardially in nude mice. One week after injection, mice (treatment group) were administered S. typhimurium A1-R (5 × 10 7 CFU, i.v.) once a week for 3 weeks. The remaining mice (control group) were administered the same volume of PBS. To evaluate metastasis-free survival, GFP-expressing lesions were initially observed using the Illumatool imaging system(Lighttools Research, Encinitas, CA) every 2 days. Metastasis-free survival was defined as the time from intracardiac injection of cancer cells to the time of detection of bone metastases with the Illumatool.
Efficacy of S. typhimurium therapy on a mouse model of solitary bone metastases
A midline skin incision (5 mm) was made just below the knee joint to expose the tibial tuberosity ( Figure 4a ). Matrigel (5 µL) (BD Bioscience, San Jose, CA) and PC-3-RFP cells (5 × 10 5 ) were co-injected into the intramedullary cavity of the tibia with a 1.0 mL 28 G latex-free insulin syringe (BD and Company, Franklin Lakes, NJ). The skin was closed with a 6-0 suture. One week after injection, fluorescence imaging was performed to confirm the RFP-expressing tumor was growing, using the iBOX Scientia (UVP LLC, Upland, CA). The study mice were randomly divided into the following groups: control group; ZOL group; S. typhimuium A1-R group; and ZOL+ S. typhimuium A1-R-group. In the ZOL group, mice were treated with subcutaneous injection of 120 mg/kg ZOL for 5 times a week for 4 weeks (Figure 4b ). S. typhimuium A1-R-group mice were administered S. typhimurium A1-R (5 × 10 7 CFU, i.v.) once a week for 3 weeks. ZOL+ S. typhimuium A1-R-group mice were administered both treatments. Fluorescence imaging was performed on treated and untreated mice, and GFPexpressing areas were recorded every week for 5 weeks using the iBOX. At the end of the follow-up, the mice were sacrificed and the metastatic tumors were excised. Tumor weight was compared to evaluate the efficacy of ZOL and S. typhimuium A1-R.
Statistical analysis
Data showing comparisons among 3 or more groups were assessed using analysis of variance (ANOVA). The Kaplan-Meier method was used for bone metastasis-free survival and overall survival. Log-rank tests were used for statistical significance of the difference between the two groups. Differences were considered significant when p < 0.05. Data are expressed as mean ± SE. Statistical analyses were performed with EZR (Saitama Medical Center, Jichi Medical University).
